EQL Pharma
50.00 SEK
+1.11 %
Less than 1K followers
EQL
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.11 %
-18.43 %
-39.76 %
-38.04 %
-38.27 %
-31.88 %
+67.79 %
+73.61 %
+830.28 %
EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.
Read moreMarket cap
1.48B SEK
Turnover
975.55K SEK
Revenue
373.52M
EBIT %
18.04 %
P/E
33.78
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
3.2
2026
Interim report Q3'26
8.5
2026
Annual report '26
All
Press releases
3rd party
ShowingAll content types
EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO)
EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools